Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx 2013 Revenues Rise Sharply

NEW YORK (GenomeWeb) – CardioDx's 2013 revenues increased more than three-fold year over year, the company said in a regulatory document on Monday.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission, the Palo Alto, Calif.-based cardiovascular molecular diagnostics firm reported $8.0 million in revenues for 2013, compared to $2.5 million in 2012. Test volume last year rose to 22,371 tests performed, up from 9,990 in 2012.

CardioDx's net loss for 2013 increased to $36.9 million from $25.6 million in 2012. Its R&D costs were up 28 percent year over year to $10.6 million from $8.3 million, while its SG&A expenses rose 78 percent to $27.0 million from $15.2 million.

The company finished the year with $3.9 million in cash and cash equivalents and $22.7 million in short-term investments.

CardioDx filed to go public in October and said the following month that it planned to offer 5 million shares of its common stock in its initial public offering at between $14 and $16 per share. At the midpoint price of $15, the IPO would raise about $77.3 million in net proceeds if the offering's underwriters exercise their overallotment option in full. The underwriters are Bank of America Merrill Lynch, Jefferies, Piper Jaffray, and William Blair.

CardioDx offers the Corus CAD, a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive coronary artery diseases.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.